All Cases

The petition was approved based on 18 peer-reviewed journal articles, 4 preprints, and 1 book chapter which garnered 577 citations. The client also demonstrated professional standing through 25 completed peer reviews and editorial service. These metrics satisfied the EB-1A criteria for scholarly articles, judging, and original contributions of major significance.

The petition was approved based on a record of 17 peer-reviewed articles and 1,210 citations, demonstrating extensive independent reliance by the research community. The petitioner also provided evidence of 13 completed manuscript reviews for respected journals. Approval was further supported by original contributions in structure-guided HIV vaccine design and nucleic acid-based strategies for SARS-CoV-2.

The petitioner submitted evidence of 38 peer-reviewed articles with 1,874 citations, placing them in the top percentile of the field. Approval was based on meeting criteria for scholarly articles, judging the work of others, and original contributions of major significance. The case demonstrated that the research is actively incorporated into clinical practice and therapeutic strategies.

Approval was based on a robust record of 74 peer-reviewed journal articles and 4 preprints with 1,777 citations, demonstrating field-wide influence. The petitioner also completed at least 40 peer reviews, signifying recognized authority. Additionally, the work attracted support from major U.S. research sponsors and state-level departments.

The petition was approved based on 6 peer-reviewed journal articles and a citation record placing the petitioner in the top 1% of highly cited authors in the delivery-systems space. Additionally, the petitioner demonstrated peer recognition through 6 completed journal reviews and received competitive support from the National Science and Technology Council of Taiwan. These metrics satisfied the EB-1A requirements for original contributions, scholarly articles, and judging.

The petition was approved based on the satisfaction of at least three EB-1A criteria, including scholarly articles, judging, and original contributions of major significance. Specific metrics included 8 peer-reviewed journal articles, 904 citations, and 15 peer review assignments for influential AI and computational venues. The case was strengthened by evidence of competitive funding from the Bill & Melinda Gates Foundation and Roche GmbH.

The petition was approved based on 21 peer-reviewed journal articles and 2,148 citations, which placed the petitioner in the top 1% of highly cited authors. Additionally, the applicant provided evidence of 36 peer reviews for prestigious journals and a granted patent. The case satisfied EB-1A criteria through scholarly articles, original contributions of major significance, and a leading/critical role in a distinguished organization.

The petition was approved based on 15 peer-reviewed journal articles and a high citation count of 1,401 with an h-index of 13. The petitioner also demonstrated authority through completing at least 30 peer-review assignments for neuroscience and biotechnology journals. These metrics satisfied the EB-1A criteria for scholarly articles, original contributions, and judging.

The approval was based on 13 peer-reviewed journal articles and 722 citations, placing the petitioner in the top 1% of cited authors. Additionally, the petitioner completed 16 peer reviews for distinguished journals and received funding from prestigious organizations like the NIH and NSF. These metrics satisfied the EB-1A criteria for scholarly articles, original contributions, and judging roles.

The petition was approved based on the petitioner's authorship of 13 peer-reviewed journal articles and a high citation count of 1,396. Additionally, the petitioner demonstrated a consistent record of professional service by conducting 28 peer reviews for distinguished journals. The research was also validated by funding from prestigious global organizations including the NIH and NSERC.